TNG (TNG) News
Follow TNG (TNG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
France's Transgene H1 operating income falls on lower tax credit
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 24, 2026, 03:56 PM UTC
L
Transgene (TNG) Reports H1 Update; Cash €92.8M, Runway to Early 2028
Transgene reported H1 2026 operating income of €3.0M, cash of €92.8M, and expects financial runway until early 2028, alongside pipeline updates for TG4050, TG4070, and TG-MVA.Material DetailsContext by AI AnalystThis is
NEWS | Sep 24, 2026, 03:51 PM UTC
L
Transgene (TNG) Files Half-Year Financial Report
Transgene announced it has filed and published its half-year financial report as of June 30, 2026, available on its website.Material DetailsContext by AI AnalystThis is a routine disclosure that updates investors with of
NEWS | Sep 24, 2026, 03:51 PM UTC
L
2026 Half-Year Financial Report
2026 Half-Year Financial ReportAttachment
NEWS | Sep 24, 2026, 03:51 PM UTC
L
Availability of Transgene’s Half-Year Financial Report as of June 30, 2026
Strasbourg, September 24, 2026, 5:45 pm CETTRANSGENE Paris:TNG today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 202
NEWS | Sep 24, 2026, 03:51 PM UTC
L
Transgene Extends its myvac(R) Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
2026 Half-Year Results and Business Updatemyvac(R) — Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturingTG4050 — First Individualized Neoanti
NEWS | Sep 24, 2026, 03:51 PM UTC
M
Transgene and NEC report 100% three-year disease-free survival
Transgene (TNG) and NEC (6701) said they report 100% three-year disease-free survival with TG4050 and plan to publish Phase 1 results in Nature Communications.
EQUITY | Sep 08, 2026, 06:03 PM UTC
L
Transgene and ProBioGen add license deal to AGE1.CR.pIX line partnership
Transgene and ProBioGen expanded their strategic partnership via an additional license agreement covering the AGE1.CR.pIX cell line, according to TradingView News.
EQUITY | Sep 08, 2026, 05:37 AM UTC
M
Transgene shares surge 20% on positive Phase 1 head-and-neck cancer vaccine data
Transgene EURONEXT:TNG shares jumped 20% in early Paris trading after the French biotech reported positive Phase 1 trial data on its head-and-neck cancer vaccine candidate.
EQUITY | Sep 03, 2026, 08:20 AM UTC
L
Transgene and Nec report 100% three-year disease-free survival with TG4050
Transgene and Nec say TG4050 showed 100% three-year disease-free survival, with a Nature Communications peer-reviewed publication highlighting Phase 1 clinical and translational findings and durable neoantigen-specific T
EQUITY | Sep 02, 2026, 04:07 PM UTC